Thomas Roehrig - Quipt Home Executive Finance
| QIPT Stock | USD 3.57 0.01 0.28% |
Executive
Thomas Roehrig is Executive Finance of Quipt Home Medical
| Age | 60 |
| Address | 1019 Town Drive, Wilder, KY, United States, 41076 |
| Phone | 859 878 2220 |
| Web | https://quipthomemedical.com |
Thomas Roehrig Latest Insider Activity
Tracking and analyzing the buying and selling activities of Thomas Roehrig against Quipt Home stock is an integral part of due diligence when investing in Quipt Home. Thomas Roehrig insider activity provides valuable insight into whether Quipt Home is net buyers or sellers over its current business cycle. Note, Quipt Home insiders must abide by specific rules, including filing SEC forms every time they buy or sell Quipt Home'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Thomas Roehrig over six months ago Disposition of 375 shares by Thomas Roehrig of Quipt Home subject to Rule 16b-3 | ||
Thomas Roehrig over a year ago Insider Trading |
Quipt Home Management Efficiency
Return On Tangible Assets is likely to drop to -0.04 in 2026. Return On Capital Employed is likely to gain to -0.01 in 2026. At this time, Quipt Home's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 342.1 M in 2026, whereas Change To Liabilities is likely to drop slightly above 1.5 M in 2026. Quipt Home's management efficiency ratios could be used to measure how well Quipt Home manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Andre CPA | DocGo Inc | 68 | |
| Ben Atkins | Avita Medical | N/A | |
| Robin VanDenburgh | Avita Medical | N/A | |
| Shawn Roman | Apyx Medical | 54 | |
| Donald MBA | Vivani Medical | 66 | |
| Arun Swaminathan | Coya Therapeutics Common | 56 | |
| Howard Berman | Coya Therapeutics Common | 52 | |
| Karen MS | Coya Therapeutics Common | N/A | |
| Donna Shiroma | Avita Medical | 61 | |
| Shane Gleason | InspireMD | 51 | |
| Vrenely Munoz | DocGo Inc | N/A | |
| Anthony Baldor | Vivani Medical | N/A | |
| Amir Kohen | InspireMD | N/A | |
| Ely JD | DocGo Inc | 58 | |
| Katie Bush | Avita Medical | N/A | |
| Edmond MD | Hyperfine | N/A | |
| Ron Lagerquist | Avita Medical | N/A | |
| Rafael OHalloran | Hyperfine | N/A | |
| Pete Ligotti | InspireMD | N/A | |
| Catherine Lundy | Xtant Medical Holdings | N/A | |
| Gregory MacMichael | Coya Therapeutics Common | 68 | |
Management Performance
| Return On Equity | -0.0931 | ||||
| Return On Asset | -0.0083 |
Quipt Home Medical Leadership Team
Elected by the shareholders, the Quipt Home's board of directors comprises two types of representatives: Quipt Home inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Quipt. The board's role is to monitor Quipt Home's management team and ensure that shareholders' interests are well served. Quipt Home's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Quipt Home's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Hardik Mehta, Chief Officer | ||
| William Zehnder, Chief Relations | ||
| Robert LLB, Corporate Secretary | ||
| Mark Miles, Vice Technology | ||
| William MD, Chief Officer | ||
| David Bachelder, Executive Operations | ||
| Gregory Crawford, President Chairman | ||
| Jerry Kirn, VP Operations | ||
| Cole Stevens, Vice Development | ||
| Leslie Becker, Exec Devel | ||
| Thomas Roehrig, Executive Finance | ||
| Patrick Gamble, Executive Operations |
Quipt Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Quipt Home a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0931 | ||||
| Return On Asset | -0.0083 | ||||
| Profit Margin | (0.04) % | ||||
| Operating Margin | 0.02 % | ||||
| Current Valuation | 263.25 M | ||||
| Shares Outstanding | 44.46 M | ||||
| Shares Owned By Insiders | 21.70 % | ||||
| Shares Owned By Institutions | 55.57 % | ||||
| Number Of Shares Shorted | 671.54 K | ||||
| Price To Earning | 98.25 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Quipt Stock Analysis
When running Quipt Home's price analysis, check to measure Quipt Home's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quipt Home is operating at the current time. Most of Quipt Home's value examination focuses on studying past and present price action to predict the probability of Quipt Home's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quipt Home's price. Additionally, you may evaluate how the addition of Quipt Home to your portfolios can decrease your overall portfolio volatility.